Enhancing CART-19 cell infiltration and antitumor response through preceding RT in vivo. (A) Working model: time line and schematic representation of in vivo A20 tumor–bearing mice treated with RT followed by CART-19 cell injection. All mice of all groups were treated with the same cyclophosphamide (CP) lymphodepletion regimen. (B-C) A20 tumor growth from irradiated and abscopal tumor (n = 17-21). (D) Survival curve after treatment administration. (E) CD45.2⁺/CD3⁺ T-cell infiltration in irradiated and abscopal tumors. (F) CD45.2^–/CD3⁺/CD45.1⁺ T-cell infiltration in irradiated and abscopal tumor representing CART-19 cells. (G) CD45.2^–/CD3⁺/CD45.1⁺ T-cell infiltration in the spleen representing CART-19 cells. Graphs show the mean ± SEM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. Data are representative of 3 independent experiments. CTR, control.